A trial of sibeprenlimab for IgA nephropathy kidney tissue
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a kidney biopsy that confirms IgA nephropathy.
- Your kidney function is above a certain level (eGFR over 45).
- You are not pregnant or breastfeeding.
- You do not have another chronic kidney disease besides IgAN.
- You have not used strong immune-suppressing drugs or high-dose steroids in the last 24 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called sibeprenlimab for children and teens with IgA nephropathy, a kidney disease. The medicine may reduce protein in the urine and help protect kidney function.
This study tests an investigational drug called SCTC21C for people with IgA nephropathy, a kidney disease caused by abnormal antibodies. The drug aims to target and reduce these harmful antibodies, which may help slow kidney damage.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.